Updated on 26 July 2012
The prices were fixed in respect of derivative formulations of the bulk drugs, namely Aspirin with Rosuvastatin (Cardiovascular), Cefotaxime (Antibacterial), Chlorpromazine with combination (Antipsychotic), Vitamine E (Tocopheryl) (Vitamin E Supplement), Streptomycin with Penicillin (Antibiotic), Norfloxacin (Antibacterial), Vitamin C with combination (Vitamin C Supplement and Antioxidant), Sulphadoxine with combination (Antimalarial), Dexamethasone with combination (Anti-inflamatory), Multivitamin with Vitamin C (Vitamin Supplement) and Insulin formulations, etc.
The necessary gazette notification orders to this effect have been issued separately. The NPPA also termed the recent media reports mentioning increased price of Insulin formulations as baseless. It also stated that the major manufacturers or importers of diabetes drug insulin, such as Eli Lilly, Cadila, Lupin and Biocon applied for upward revision in the retail price of insulin. However, keeping the interest of consumers and to ensure abundant availability of insulin formulations at reasonable prices, the insulin formulations prices have been maintained at the existing level by suitably adjusting the profit margin.